Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Small-cell lung cancer (SCLC) is a highly proliferative, rapidly growing tumor with a poor prognosis, even in cases of limited disease (LD). Timely and accurate high-intensity therapy is necessary. For concurrent chemoradiotherapy (CCRT), etoposide/platinum (EP)-based regimens are recommended, although irinotecan/platinum (IP)-based regimens are also effective with radiotherapy. This large-scale, retrospective, nationwide cohort study aimed to analyze the efficacy of CCRT in patients with LD-SCLC.
Methods: Population data registered between January 2008 and December 2018 was extracted from the Health Insurance Review and Assessment Service of Korea database. Survival outcomes of 4446 LD-SCLC patients who received CCRT were analyzed.
Results: Patients who received EP-CCRT (n = 4187) showed better time to first subsequent therapy (TFST: 11.2 months) and overall survival (OS: 22.2 months) than those who received IP-CCRT (n = 259; TFST: 9.6 months, P = 0.0477; OS: 16.4 months, P < 0.0001). When CCRT failed, dual-agent chemotherapy (n = 925; OS: 9.1 months) provided a better survival benefit than single-agent chemotherapy (n = 815; OS: 7.5 months). IP-based chemotherapy resulted in better OS (9.6 months) than EP-based chemotherapy (7.1 months, P = 0.017) in platinum-resistant relapsed patients; the opposite was observed for platinum-sensitive relapsed patients (OS: EP, 17.2 months; IP, 6.6 months; P < 0.0001). Poisson regression analysis demonstrated that age, EP-CCRT, and hypercholesterolemia retained significant associations with OS after adjustment for all variables.
Conclusion: In the Korean population, the effects of EP-CCRT on OS and TFST are significantly more favorable than those of IP-CCRT.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011172 | PMC |
| http://dx.doi.org/10.1186/s12885-021-08082-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Robotic versus laparoscopic total mesorectal excision for mid-low rectal cancer after neoadjuvant chemoradiotherapy: a systematic review and meta-analysis of oncological, perioperative, and survival-related outcomes.
J Robot Surg
September 2025
Department of Oncology, Shengli Oilfield Central Hospital, Dongying, China.
A major cause of cancer death, colorectal cancer is becoming more common in younger people. The comparative effectiveness of robotic versus laparoscopic total mesorectal excision (TME) as surgical interventions for mid-low rectal cancer following neoadjuvant chemoradiotherapy (nCRT) remains uncertain. To systematically evaluate oncological, perioperative, and survival outcomes of robotic versus laparoscopic surgery for mid-low rectal cancer following nCRT.
View Article and Find Full Text PDFProspective Evaluation of Patient Priorities in HPV-Driven Oropharyngeal Cancer Using the Chicago Priorities Scale: Considerations for Future Clinical Trial Design.
Int J Radiat Oncol Biol Phys
September 2025
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, Australia; Department of Nursing, Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne,
Purpose: This study examined head and neck cancer treatment outcome priorities in patients with human papillomavirus-associated oropharyngeal cancer (HPVOPC) before and 12 months (12m) after (chemo)radiotherapy ([C]RT).
Methods And Materials: Eligible patients were diagnosed with HPVOPC suitable for curative-intent primary [C]RT. Study data included responses to a modified version of the Chicago Priorities Scale (CPS-modified) and select items from the MDASI Head and Neck Cancer Module (MDASI-HN).
ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma.
Cell Rep Med
August 2025
Department of Thoracic Surgery, Shanghai Key Laboratory of Thoracic Tumor Biotherapy, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; Shanghai Institute of Thoracic Oncology, Shanghai 200030, China. Electronic address:
The diagnostic accuracy of circulating tumor DNA (ctDNA) for detecting molecular residual disease (MRD) after multimodal treatment remains unclear. In a prospective cohort of 132 patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemoradiotherapy (nCRT) followed by clinical response evaluation and surgery, tumor-informed personalized-panel and fixed-panel ctDNA assays are applied to serial blood samples. Personalized ctDNA assay demonstrates a superior baseline detection rate (99.
View Article and Find Full Text PDFEfficacy and safety of induction immunotherapy plus chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Br J Cancer
September 2025
Department of Oncology, Heyuan People's Hospital, Guangdong Provincial People's Hospital Heyuan Hospital, Heyuan, Guangdong, China.
Background: Locally advanced nasopharyngeal carcinoma (LA-NPC) has a heterogeneous prognosis, with approximately one-fourth of patients experiencing poor outcomes. Studies have explored the application of induction chemoimmunotherapy followed by chemoradiotherapy, but its efficacy was controversial.
Methods: The protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO, CRD42024619387).
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?
ESMO Open
September 2025
Department of Thoracic Surgery, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Pancoast tumors are a distinct and rare subset of non-small-cell lung cancers (NSCLCs). Although a trimodality approach combining induction chemoradiotherapy followed by surgery has been the standard of care over the past two decades, only a limited number of patients are eligible for this intensive treatment in routine clinical practice. Moreover, surgical procedures for Pancoast tumors often require highly specialized thoracic surgery centers.
View Article and Find Full Text PDF